Journal of Medicinal Chemistry · 2023 · 32 citations · 67 references
PharmacyMedicinal ChemistryPharmacologyDrug DiscoveryMolecular PharmacologyOrganic ChemistryBioactive Small MoleculesEnzyme InhibitionMarine Bioactive CompoundsMarine Natural ProductsNatural Product Drug DiscoveryTyrosine Kinase InhibitorsKinase InhibitorsKinase Signaling InhibitorsMarine Sponge MetabolitesMarine-derived Drug DiscoveryMarine-derived Enzyme InhibitorsProtein Kinase InhibitorsProtein Tyrosine PhosphorylationTyrosine Phosphorylation Signaling
Dual-specificity, tyrosine phosphorylation-regulated kinases (DYRKs) and cdc2-like kinases (CLKs) recently attracted attention due to their central involvement in various pathologies. We here describe a family of DYRK/CLK inhibitors derived from Leucettines and the marine natural product Leucettamine B. Forty-five N 2-functionalized 2-aminoimidazolin-4-ones bearing a fused [6 + 5]-heteroarylmethylene were synthesized. Benzothiazol-6-ylmethylene was selected as the most potent residue among 15 different heteroarylmethylenes. 186 N 2-substituted 2-aminoimidazolin-4-ones bearing a benzothiazol-6-ylmethylene, collectively named Leucettinibs, were synthesized and extensively characterized. Subnanomolar IC 50 (0.5–20 nM on DYRK1A) inhibitors were identified and one Leucettinib was modeled in DYRK1A and co-crystallized with CLK1 and the weaker inhibited off-target CSNK2A1. Kinase-inactive isomers of Leucettinibs (>3–10 μM on DYRK1A), named iso-Leucettinibs, were synthesized and characterized as suitable negative control compounds for functional experiments. Leucettinibs, but not iso-Leucettinibs, inhibit the phosphorylation of DYRK1A substrates in cells. Leucettinibs provide new research tools and potential leads for further optimization toward therapeutic drug candidates.
67
Wolfgang Kabsch · Acta Crystallographica Section D Biological Crystallography · 2010 · 16.9K citations · Full text